| Title |
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial
|
|---|---|
| Published in |
Lancet Oncology, May 2016
|
| DOI | 10.1016/s1470-2045(16)30051-1 |
| Pubmed ID | |
| Authors |
Barbara Eichhorst, Anna-Maria Fink, Jasmin Bahlo, Raymonde Busch, Gabor Kovacs, Christian Maurer, Elisabeth Lange, Hubert Köppler, Michael Kiehl, Martin Sökler, Rudolf Schlag, Ursula Vehling-Kaiser, Georg Köchling, Christoph Plöger, Michael Gregor, Torben Plesner, Marek Trneny, Kirsten Fischer, Harmut Döhner, Michael Kneba, Clemens-Martin Wendtner, Wolfram Klapper, Karl-Anton Kreuzer, Stephan Stilgenbauer, Sebastian Böttcher, Michael Hallek, international group of investigators, German CLL Study Group |
X Demographics
The data shown below were collected from the profiles of 22 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 7 | 32% |
| Spain | 1 | 5% |
| Australia | 1 | 5% |
| Japan | 1 | 5% |
| France | 1 | 5% |
| Unknown | 11 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 11 | 50% |
| Practitioners (doctors, other healthcare professionals) | 6 | 27% |
| Scientists | 4 | 18% |
| Science communicators (journalists, bloggers, editors) | 1 | 5% |
Mendeley readers
The data shown below were compiled from readership statistics for 471 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| Denmark | 1 | <1% |
| Canada | 1 | <1% |
| Unknown | 468 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 58 | 12% |
| Other | 47 | 10% |
| Student > Ph. D. Student | 47 | 10% |
| Student > Bachelor | 46 | 10% |
| Student > Master | 43 | 9% |
| Other | 94 | 20% |
| Unknown | 136 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 197 | 42% |
| Biochemistry, Genetics and Molecular Biology | 33 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 22 | 5% |
| Agricultural and Biological Sciences | 17 | 4% |
| Nursing and Health Professions | 15 | 3% |
| Other | 39 | 8% |
| Unknown | 148 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 61. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 April 2024.
All research outputs
#716,303
of 25,927,633 outputs
Outputs from Lancet Oncology
#898
of 6,973 outputs
Outputs of similar age
#13,334
of 350,354 outputs
Outputs of similar age from Lancet Oncology
#21
of 163 outputs
Altmetric has tracked 25,927,633 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,973 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.2. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 350,354 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 163 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.